Shopping Cart
- Remove All
- Your shopping cart is currently empty
Iladatuzumab vedotin (DCDS-0780A), an antibody-drug conjugate (ADC), is a fusion of a humanized IgG1 anti-human CD79B monoclonal antibody (MCDS0593A) and the cytotoxic agent MMAE, linked through a protease-labile linker. Utilizing novel THIOMAB technology (TDC), it achieves precise conjugation of two MMAE molecules per antibody via engineered cysteine residues. This compound holds promise for research in B-cell non-Hodgkin lymphoma (B-NHL) [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | Iladatuzumab vedotin (DCDS-0780A), an antibody-drug conjugate (ADC), is a fusion of a humanized IgG1 anti-human CD79B monoclonal antibody (MCDS0593A) and the cytotoxic agent MMAE, linked through a protease-labile linker. Utilizing novel THIOMAB technology (TDC), it achieves precise conjugation of two MMAE molecules per antibody via engineered cysteine residues. This compound holds promise for research in B-cell non-Hodgkin lymphoma (B-NHL) [1]. |
Alias | DCDS-0780A |
Cas No. | 1906205-77-3 |
Storage | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.